Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Therapeutic Area Key Developments<br />
RESPIRATORY/ALLERGIES<br />
ANTI-INFECTIVES<br />
ARTHRITIS/OSTEOPOROSIS<br />
CENTRAL NERVOUS SYSTEM<br />
(5)<br />
(3)<br />
(6)<br />
· Telfast 30 mg tablets receive EU approval for pediatric use (6-11 years)<br />
· A New Drug Application for Allegra-D 24 hour tablet is submitted to<br />
the FDA in December<br />
· Patient preference study confirms that Nasacort AQ is preferred by<br />
patients 2 to 1 over competing products based on sensory attributes<br />
· Nasacort aerosol nasal inhaler removed from the market in July <strong>2003</strong><br />
in compliance with the Montreal Protocol<br />
· Approved and launched in Canada, Japan and Turkey<br />
· Achieves status as best antibiotic launch in France, Mexico,<br />
Belgium, Greece, Turkey and Finland<br />
· Submitted in the UK (EU-RMS) (4) for the treatment of prostatitis<br />
· Approved in the UK (EU-RMS) for the treatment of uncomplicated<br />
urinary tract infections<br />
· Approved for pediatric use in Japan<br />
· Leading antibiotic for the treatment of serious Gram-positive<br />
infections in Japan and the UK<br />
· New 35 mg once-weekly formulation successfully launched in<br />
major European and International markets<br />
· Differentiation achieved by establishing bone quality as a key<br />
measure of bone health<br />
· Receives FDA approval for additional indication to improve physical<br />
function in rheumatoid arthritis<br />
· Approved and launched in Japan<br />
· Launched in French pharmacies in September <strong>2003</strong><br />
· Continued excellent market penetration in Europe<br />
· Fastest-growing multiple sclerosis therapy worldwide<br />
Important notice: The therapeutic indications mentioned in this document do<br />
not necessarily correspond to the exact indications registered in every country<br />
where the relevant pharmaceutical products are marketed and sold. The<br />
products identified in this document are only a selection of the total product<br />
offering of <strong>Aventis</strong>.<br />
<strong>2003</strong> Key Figures<br />
Sales (in e million) Activity Variance*<br />
1 736 1.1 %<br />
278 -0.7 %<br />
115 135 %<br />
216 -12.3 %<br />
207 -1.1 %<br />
194 81.4 %<br />
255 8.3 %<br />
617 27.3 %<br />
(1) Licensed from Yakult Honsha (not sold by <strong>Aventis</strong> in the United States)<br />
(2) Includes sales by the joint venture <strong>Aventis</strong> Pasteur MSD, which is accounted for<br />
using the equity method<br />
(3) Licensed from Daiichi (not sold by <strong>Aventis</strong> in the United States)<br />
(4) EU-RMS = European Union Reference Member State<br />
(5) Sold in cooperation with Procter & Gamble Pharmaceuticals; sales consolidated by <strong>Aventis</strong><br />
(6) Sold in cooperation with Teva Pharmaceutical Industries